JP2017525364A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017525364A5 JP2017525364A5 JP2017509626A JP2017509626A JP2017525364A5 JP 2017525364 A5 JP2017525364 A5 JP 2017525364A5 JP 2017509626 A JP2017509626 A JP 2017509626A JP 2017509626 A JP2017509626 A JP 2017509626A JP 2017525364 A5 JP2017525364 A5 JP 2017525364A5
- Authority
- JP
- Japan
- Prior art keywords
- mesenchymal stem
- stem cell
- genetically modified
- promoter
- modified mesenchymal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims 38
- 206010028980 Neoplasm Diseases 0.000 claims 16
- 102000004127 Cytokines Human genes 0.000 claims 15
- 108090000695 Cytokines Proteins 0.000 claims 15
- 238000011398 antitumor immunotherapy Methods 0.000 claims 14
- 230000028993 immune response Effects 0.000 claims 14
- 230000004936 stimulating effect Effects 0.000 claims 14
- 108010012236 Chemokines Proteins 0.000 claims 9
- 102000019034 Chemokines Human genes 0.000 claims 9
- 210000002865 immune cell Anatomy 0.000 claims 9
- 108010002586 Interleukin-7 Proteins 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 239000003623 enhancer Substances 0.000 claims 6
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 5
- 108010065805 Interleukin-12 Proteins 0.000 claims 5
- 102100030704 Interleukin-21 Human genes 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 5
- 108010074108 interleukin-21 Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 4
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims 4
- 108090000172 Interleukin-15 Proteins 0.000 claims 4
- 108010002350 Interleukin-2 Proteins 0.000 claims 4
- 102100036842 C-C motif chemokine 19 Human genes 0.000 claims 2
- 102100036850 C-C motif chemokine 23 Human genes 0.000 claims 2
- -1 CCL22 Proteins 0.000 claims 2
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 claims 2
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 239000012270 PD-1 inhibitor Substances 0.000 claims 2
- 239000012668 PD-1-inhibitor Substances 0.000 claims 2
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims 2
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims 2
- 230000006052 T cell proliferation Effects 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000035605 chemotaxis Effects 0.000 claims 2
- 230000004069 differentiation Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 238000011133 mesenchymal stem cell therapy Methods 0.000 claims 2
- 210000001616 monocyte Anatomy 0.000 claims 2
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 2
- 230000035899 viability Effects 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 claims 1
- 108010055166 Chemokine CCL5 Proteins 0.000 claims 1
- 102000006573 Chemokine CXCL12 Human genes 0.000 claims 1
- 108010008951 Chemokine CXCL12 Proteins 0.000 claims 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 claims 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 claims 1
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 210000002536 stromal cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14181283.4 | 2014-08-18 | ||
| EP14181283 | 2014-08-18 | ||
| PCT/EP2015/068942 WO2016026854A2 (en) | 2014-08-18 | 2015-08-18 | Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017525364A JP2017525364A (ja) | 2017-09-07 |
| JP2017525364A5 true JP2017525364A5 (enExample) | 2018-09-20 |
| JP6712993B2 JP6712993B2 (ja) | 2020-06-24 |
Family
ID=51352460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017509626A Active JP6712993B2 (ja) | 2014-08-18 | 2015-08-18 | 免疫細胞を惹起及び／又は活性化するための免疫応答刺激性サイトカインを発現する遺伝子改変型間葉系幹細胞 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20170239297A1 (enExample) |
| EP (2) | EP3182984B1 (enExample) |
| JP (1) | JP6712993B2 (enExample) |
| CN (1) | CN106659742B (enExample) |
| AU (1) | AU2015306231B2 (enExample) |
| CA (1) | CA2956987C (enExample) |
| IL (1) | IL250388B (enExample) |
| WO (1) | WO2016026854A2 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201202319D0 (en) | 2012-02-10 | 2012-03-28 | Orbsen Therapeutics Ltd | Stromal stem cells |
| WO2015124297A1 (en) * | 2014-02-19 | 2015-08-27 | Merck Patent Gmbh | Cancer-targeted il-12 immunotherapy |
| JP6971986B2 (ja) * | 2016-04-01 | 2021-11-24 | アプセト ゲーエムベーハー アンド ツェーオー．カーゲー | 免疫療法の抗腫瘍活性を高めるための間葉系幹細胞 |
| WO2018071295A1 (en) * | 2016-10-10 | 2018-04-19 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for inducible production of anti-inflammatory cytokines |
| CN108148862B (zh) | 2016-12-05 | 2019-03-08 | 上海优卡迪生物医药科技有限公司 | 一种封闭pdl1的用于抑制免疫逃脱的car-t转基因载体及其构建方法和应用 |
| JP2020509773A (ja) * | 2017-03-17 | 2020-04-02 | センティ バイオサイエンシズ インコーポレイテッド | 免疫調節性細胞回路 |
| KR20190133254A (ko) * | 2017-04-07 | 2019-12-02 | 시나타 세라퓨틱스 엘티디 | 키메라 항원 수용체 (car) t 세포 요법의 부작용을 치료하는 방법 |
| KR20190141695A (ko) * | 2017-04-13 | 2019-12-24 | 센티 바이오사이언시스, 인코포레이티드 | 병용 암 면역요법 |
| CN107184603B (zh) * | 2017-06-01 | 2020-06-30 | 刘未斌 | 一种治疗肿瘤的药物组合 |
| CN107184602B (zh) * | 2017-06-01 | 2020-06-30 | 刘未斌 | 一种治疗肿瘤的药物组合 |
| CA3066799A1 (en) * | 2017-06-16 | 2018-12-20 | Cynata Therapeutics Limited | Method for treating a side effect of immunotherapy |
| WO2019067491A1 (en) * | 2017-09-29 | 2019-04-04 | Oncocyclist, Inc. | COMPOSITION AND METHOD FOR TREATING CELL PROLIFERATION |
| US12016882B2 (en) | 2017-11-22 | 2024-06-25 | The Brigham And Women's Hospital, Inc. | Method of treating glioblastoma multiforme |
| TR201900059A2 (tr) | 2018-01-05 | 2019-07-22 | Gnt Biotech & Medicals Corp | Bi̇r farmasöti̇k kombi̇nasyon ve tümör mi̇kroortaminin ve i̇mmünoterapi̇ni̇n regülasyonu i̇çi̇n yöntem |
| AU2019206643A1 (en) * | 2018-01-12 | 2020-07-23 | Rutgers, The State University Of New Jersey | Cell reprogramming therapy |
| JP7102670B2 (ja) * | 2018-01-25 | 2022-07-20 | アイ－エムエービー バイオファーマ ユーエス リミテッド | 抗ｐｄ‐ｌ１抗体とｉｌ‐７との融合 |
| JP2021512950A (ja) * | 2018-02-02 | 2021-05-20 | エスエル・ベクシジェン・インコーポレイテッドＳｌ Ｖａｘｉｇｅｎ， Ｉｎｃ． | 新規なワクチンの免疫補助剤 |
| CN111836888B (zh) * | 2018-03-21 | 2024-01-12 | 洪明奇 | 用于癌症治疗的工程化干细胞 |
| CN108864288A (zh) * | 2018-04-26 | 2018-11-23 | 上海怡豪生物科技有限公司 | 乳腺癌的双靶点car-t治疗载体及其构建方法和应用 |
| CN110527696A (zh) * | 2018-06-13 | 2019-12-03 | 中山大学 | 一种IFNβ和FerritinH基因联合修饰的骨髓间充质干细胞及其制备方法和应用 |
| CN108815188A (zh) * | 2018-07-06 | 2018-11-16 | 浙江生创精准医疗科技有限公司 | 包含间充质干细胞制剂与免疫检查点抑制剂的肿瘤治疗组合物、试剂盒及其用途 |
| CN112384231A (zh) * | 2018-08-26 | 2021-02-19 | 奥伊斯细胞生物技术公司 | 用于治疗胶质母细胞瘤的方法 |
| CN112771167B (zh) * | 2018-09-20 | 2025-09-26 | 克莱格医学有限公司 | 表达有趋化因子的细胞及用途 |
| US20210338729A1 (en) * | 2018-10-12 | 2021-11-04 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs) COMPOSITIONS AND METHODS OF USE THEREOF |
| CA3116138A1 (en) * | 2018-10-17 | 2020-04-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| CN109593725A (zh) * | 2018-12-25 | 2019-04-09 | 河北生命原点生物科技有限公司 | 一种重组间充质干细胞及其应用 |
| MX2021009785A (es) * | 2019-02-14 | 2021-09-08 | Res Institute At Nationwide Children´S Hospital | Uso de particulas de membrana plasmatica, liposomas y exosomas para evaluar la potencia de celulas inmunitarias. |
| CN109762820B (zh) * | 2019-02-18 | 2020-07-28 | 河北佑仁生物科技有限公司 | 一种骨髓间充质干细胞特异性启动元件在干细胞中的应用 |
| US20220143099A1 (en) * | 2019-04-02 | 2022-05-12 | The General Hospital Corporation | Methods to enhance t cell regeneration |
| CN115851605A (zh) * | 2019-04-18 | 2023-03-28 | 上海交通大学 | 间充质干细胞靶向运输趋化因子和细胞因子的免疫疗法 |
| CN111139222B (zh) * | 2019-05-30 | 2020-12-29 | 北京双因生物科技有限公司 | 一种重组间充质干细胞及其制备方法和用途 |
| EP4556072A3 (en) * | 2019-08-23 | 2025-06-11 | Orbsen Therapeutics Limited | Compositions for monocyte and macrophage polarization and methods of use |
| US20230105923A1 (en) * | 2020-03-26 | 2023-04-06 | Agency For Science, Technology And Research | A method and system for introducing one or more exogenous substances into an immune cell |
| JP7820823B2 (ja) * | 2020-05-27 | 2026-02-26 | ウニヴェルジテート・チューリッヒ | 骨髄性細胞およびミクログリアにおいて特異的に治療タンパク質を発現するウイルスベクター |
| JP7758370B2 (ja) * | 2020-07-16 | 2025-10-22 | チャンジェン セラピューティクス （シャンハイ） カンパニー リミテッド | 間葉系幹細胞によるケモカインおよびサイトカイン送達を標的とする免疫療法 |
| WO2022079322A1 (en) * | 2020-10-16 | 2022-04-21 | Fundació Centre De Regulació Genòmica | Therapy for degenerative disease and tissue damage |
| CN114507643A (zh) * | 2020-10-29 | 2022-05-17 | 未来智人再生医学研究院(广州)有限公司 | 一种表达il-2的多能干细胞衍生物及应用 |
| CN114426953A (zh) * | 2020-10-29 | 2022-05-03 | 未来智人再生医学研究院(广州)有限公司 | 一种表达il-12的多能干细胞衍生物及应用 |
| CN114717232A (zh) * | 2020-12-22 | 2022-07-08 | 未来智人再生医学研究院(广州)有限公司 | 表达irf-1靶向抑制因子的多能干细胞及其衍生物与应用 |
| WO2023274355A1 (zh) * | 2021-07-02 | 2023-01-05 | 上海交通大学 | 改造的间充质干细胞和免疫效应细胞联合治疗肿瘤 |
| WO2023076670A1 (en) * | 2021-11-01 | 2023-05-04 | MAM Holdings of West Florida, L.L.C. | Mesenchymal stem cells for the prevention and targeted treatment of cancer and other disorders |
| CN114480413B (zh) * | 2022-01-14 | 2022-11-04 | 北京贝来生物科技有限公司 | 一种活化肿瘤免疫应答的基因修饰干细胞制备方法 |
| CN115463155B (zh) * | 2022-11-01 | 2023-05-23 | 卡瑞济(北京)生命科技有限公司 | 间充质干细胞的用途 |
| CN117503952B (zh) * | 2022-11-24 | 2025-09-16 | 中国药科大学 | 一种基于血小板的免疫激活系统及其制备方法和应用 |
| WO2024137869A2 (en) * | 2022-12-20 | 2024-06-27 | City Of Hope | Stem cells for delivery of oncolytic viruses |
| US12655391B2 (en) * | 2024-02-28 | 2026-06-16 | Gene Solutions Joint Stock Company | Modified K562 feeder cell line expressing factors that enhance the activation and proliferation of natural killer cells and a method for its production |
| WO2026069312A1 (en) | 2024-09-24 | 2026-04-02 | Yeda Research And Development Co. Ltd. | Immune cells expressing an inducible therapeutic agent and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040076622A1 (en) | 2002-03-02 | 2004-04-22 | Board Of Regents, The University Of Texas System | Local production and/or delivery of anti-cancer agents by stromal cell precursors |
| KR101130220B1 (ko) * | 2003-06-27 | 2012-04-13 | 엔씨 메디컬 리서치 가부시키가이샤 | 간엽계 세포를 유효 성분으로 하는 뇌신경 질환 치료용 체내 투여용 약제 |
| WO2005001732A1 (ja) * | 2003-06-27 | 2005-01-06 | Renomedix Institute Inc. | 治療用自己細胞配送支援システム及び治療用自己細胞配送支援金融システム、並びにそれらの方法 |
| US20050002904A1 (en) | 2003-07-03 | 2005-01-06 | Wary Kishore K. | Uses of vascular endothelial growth factor and type I collagen inducible protein (VCIP) |
| RU2007113444A (ru) * | 2004-09-10 | 2008-10-27 | Когнейт Терапьютикс | Стромальные клетки печени для профилактики и лечения иммунных реакций при трансплантации |
| EP1757703A3 (en) | 2005-08-24 | 2007-12-05 | Medizinische Hochschule Hannover | Self-inactivating retroviral vector |
| ES2507507T3 (es) * | 2007-05-24 | 2014-10-15 | Apceth Gmbh & Co. Kg | Células madre mesenquimales CD34 negativas modificadas genéticamente para el tratamiento de tumores |
| EP2019134A1 (en) | 2007-07-26 | 2009-01-28 | Vision 7 GmbH | Gene therapy of chronic granulomatous disease |
| JP5727458B2 (ja) * | 2009-04-13 | 2015-06-03 | アプセト ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフトＡｐｃｅｔｈ Ｇｍｂｈ ＆ Ｃｏ． Ｋｇ | 改変間葉系幹細胞及びそれを使用した腫瘍の治療方法 |
| DK2510084T3 (da) * | 2009-12-08 | 2020-04-27 | The Board Of Trustees Of The Univ Of Illionis | Stamcelleimmunmoduleringsanvendelsesfremgangsmåder og apparat |
| CN101974485A (zh) * | 2010-11-12 | 2011-02-16 | 苏州大学 | 具有最佳迁移能力的间充质干细胞的制备方法及其应用 |
| US9101597B2 (en) | 2013-03-14 | 2015-08-11 | The Administration Of The Tulane Educational Fund | Immunoprotective primary mesenchymal stem cells and methods |
| AR097570A1 (es) * | 2013-09-06 | 2016-03-23 | Consejo Nac De Investig Científicas Y Técnicas (Conicet) | Composiciones y métodos para incrementar la migración de células mesenquimales del estroma hacia tumores |
| EP3097117B1 (en) * | 2014-01-21 | 2023-10-04 | Novartis Ag | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| WO2016146819A1 (en) * | 2015-03-18 | 2016-09-22 | Apceth Gmbh & Co. Kg | Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells |
-
2015
- 2015-08-18 US US15/504,554 patent/US20170239297A1/en not_active Abandoned
- 2015-08-18 CA CA2956987A patent/CA2956987C/en active Active
- 2015-08-18 EP EP15759667.7A patent/EP3182984B1/en active Active
- 2015-08-18 CN CN201580045089.6A patent/CN106659742B/zh active Active
- 2015-08-18 JP JP2017509626A patent/JP6712993B2/ja active Active
- 2015-08-18 EP EP19205297.5A patent/EP3656387A3/en not_active Withdrawn
- 2015-08-18 AU AU2015306231A patent/AU2015306231B2/en not_active Ceased
- 2015-08-18 WO PCT/EP2015/068942 patent/WO2016026854A2/en not_active Ceased
-
2017
- 2017-02-01 IL IL250388A patent/IL250388B/en active IP Right Grant
-
2020
- 2020-01-28 US US16/774,495 patent/US11464806B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dobrzanski | Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy | |
| Brempelis et al. | Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses | |
| Xie et al. | The role of CD4+ T cells in tumor and chronic viral immune responses | |
| Lee et al. | The dual nature of type I and type II interferons | |
| Zhang et al. | Interplay between inflammatory tumor microenvironment and cancer stem cells | |
| US11464806B2 (en) | Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells | |
| Alpdogan et al. | IL-7 and IL-15: therapeutic cytokines for immunodeficiency | |
| Setrerrahmane et al. | Tumor-related interleukins: old validated targets for new anti-cancer drug development | |
| Christopherson et al. | Chemokine regulation of normal and pathologic immune responses | |
| Curtsinger et al. | Autocrine IFN-γ promotes naive CD8 T cell differentiation and synergizes with IFN-α to stimulate strong function | |
| Mitchell et al. | Distinct roles for IL-2 and IL-15 in the differentiation and survival of CD8+ effector and memory T cells | |
| Dieu‐Nosjean et al. | Tertiary lymphoid structures, drivers of the anti‐tumor responses in human cancers | |
| Stoycheva et al. | IFN-γ regulates CD8+ memory T cell differentiation and survival in response to weak, but not strong, TCR signals | |
| Hervas-Stubbs et al. | CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy | |
| JP2019509715A5 (enExample) | ||
| Ogata et al. | Plasmacytoid dendritic cells have a cytokine-producing capacity to enhance ICOS ligand-mediated IL-10 production during T-cell priming | |
| JP2018526450A5 (enExample) | ||
| Kagoya | Cytokine signaling in chimeric antigen receptor T-cell therapy | |
| JP2018528774A5 (enExample) | ||
| JP2018514199A5 (enExample) | ||
| JP2012504959A5 (enExample) | ||
| JP2019536457A5 (enExample) | ||
| WO2018183169A4 (en) | Ank and il-12 compositions and methods | |
| Willemen et al. | Engineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functions | |
| Kokaji et al. | IL-15 transpresentation augments CD8+ T cell activation and is required for optimal recall responses by central memory CD8+ T cells |